REG - Aptamer Group PLC - Notice of Results, Analyst & Investor Presentation

AptamerAnnouncement

10/10/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251010:nRSJ8261Ca&default-theme=true

RNS Number : 8261C  Aptamer Group PLC  10 October 2025

10 October 2025

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

Notice of Results

Analyst Briefing and Investor Presentation

 

Aptamer Group plc (AIM: APTA), the leading developer of next-generation
synthetic binders delivering innovation to the life science industry, will
announce its full year results for the year ended 30 June 2025 on Tuesday, 14
October 2025 and hold the following analyst briefing and investor
presentation.

 

Analyst briefing

 

An online briefing for analysts will be hosted by Dr Arron Tolley, Chief
Executive Officer and Andrew Rapson, Chief Financial Officer, at 9.30 am on
Tuesday, 14 October 2025, to review the full year results. Analysts wishing to
attend should contact Sarah Hollins at Northstar Communications at
sarah@northstarcommunications.co.uk.

 

Investor presentation

 

An investor presentation to cover the full year results will be held at 2.00
pm on Tuesday, 14 October 2025.

 

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard or at any
time during the live presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet
Aptamer Group plc via:

https://www.investormeetcompany.com/aptamer-group-plc/register-investor
(https://www.investormeetcompany.com/aptamer-group-plc/register-investor)

 

Investors who already follow Aptamer Group plc on the Investor Meet Company
platform will automatically be invited.

 

- Ends -

 

For further information, please contact:

 

 Aptamer Group plc                                               +44 (0) 1904 217 404 

 Dr Arron Tolley, Chief Executive Officer
 SPARK Advisory Partners Limited - Nominated Adviser             +44 (0) 20 3368 3550 

 Andrew Emmott  
 Turner Pope Investments (TPI) Limited - Broker                  +44 (0) 20 3657 0050 

 James Pope / Andrew Thacker 
 Northstar Communications Limited - Investor Relations           +44 (0) 113 730 3896

 Sarah Hollins

 

About Aptamer Group

 

Aptamer Group is a leading developer of next-generation synthetic binders
delivering innovation to the life sciences industry. The Group develops
Optimer® binders, advanced molecules that work like antibodies by attaching
to specific targets in the body. These binders are used in medicine,
diagnostic tests, and research tools, offering benefits like high stability,
reliable performance, and lower costs compared to traditional antibodies.

 

Aptamer operates a fee-for-service business in the US$210 billion market for
antibody alternatives, working with all top 10 global pharmaceutical
companies. It is also building valuable Optimer® assets with partners, aiming
for future licensing revenue.

 

Founded in 2008, the Group listed on the London Stock Exchange AIM market in
December 2021 and is headquartered in York, UK.

 

To register for news alerts by email go to
https://aptamergroup.com/investors/investor-news-email-alerts/
(https://aptamergroup.com/investors/investor-news-email-alerts/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORZZMGGGLGGKZZ